MS Prevalence at Over 2.8 Million Worldwide, Update to Atlas Reports
More than 2.8 million people worldwide are now estimated to be living with multiple sclerosis (MS), including about 1…
Articles by Marisa Wexler, MS
Progressive MS Trial of Kesimpta Not on Horizon, But Other Possibilities in Works
Novartis is not planning to open a clinical trial of Kesimpta (ofatumumab) as a potential treatment for primary progressive multiple…
New and Ongoing Trials Evaluating Kesimpta, Including as Switch Therapy
Upcoming and ongoing clinical trials aim to expand an understanding of Kesimpta (ofatumumab), the Novartis therapy recently approved by the …
Kesimpta Meets Safety, Efficacy and Flexibility Needs of Relapsing MS, Experts Say
Kesimpta (ofatumumab) is a safe and effective treatment for relapsing multiple sclerosis (MS), with an ease of delivery…
MMJ International Holdings Manufacturing Cannabis-based Investigational Therapies for MS, Huntington’s
MMJ International Holdings, in collaboration with a a specialty pharmaceutical solutions company, has begun manufacturing gelatin…
Mechanism Controlling Remyelination May Have MS Therapy Implications, Study Finds
Chemical modification of the protein eukaryotic elongation factor 1A1 (eEF1A1) regulates remyelination, a new study suggests, indicating that the…
FDA Approves Kesimpta, B-cell Targeting Therapy for Relapsing MS
The U.S. Food and Drug Administration (FDA) has approved Novartis‘ Kesimpta (ofatumumab) as a self-administered treatment for…
Mylan Launching Tecfidera Generic in US
Mylan announced the launch of a first generic version of Tecfidera, a treatment for relapsing forms of…
Study Reveals Increased Cellular Stress in MS Skin Fibroblasts
In people with multiple sclerosis (MS), skin cells show increased amounts of cellular stress in a manner that is…
Ofatumumab Seen as Superior to Aubagio at Lowering Relapse Rates in Phase 3 Trials
Novartis‘ ofatumumab outperformed Aubagio (teriflunomide) at lowering the frequency of relapses and preventing disability progression among people with…
Oral RRMS Therapy Safely Lowers Active Lesions in Phase 2 Trial, Data Show
Immunic Therapeutics‘s IMU-838, a selective immune system modulator, can safely lower the number of brain lesions in…
Canadian MS Working Group Updates Guidelines for Diagnosis, Treatment
The Canadian MS Working Group (CMSWG) — made up of neurologists with the Canadian Network of MS Clinics — has…
Ketamine May Help Treat MS-related Fatigue, Small Pilot Trial Suggests
Low doses of the anesthetic ketamine could help treat fatigue in people with multiple sclerosis (MS), according…
Cognitive Health Tests Given Online Show ‘Promise’ in Study
Assessing the cognitive health of people with multiple sclerosis (MS) can be performed using online telehealth, with results…
Tysabri Use Can Lessen Disability in RRMS Patients, Real-world Study Reports
Treatment with Tysabri (natalizumab) can lessen disability in people with relapsing-remitting multiple sclerosis (RRMS), a large and real-world study found,…
Most RIS Patients Likely to Progress to MS Within 10 Years, Study Says
More than half of people with brain imaging changes akin to multiple sclerosis (MS) go on to develop the…
Alternative Medicine Popular With MS Patients in US Northwest, Survey Finds
Complementary and alternative medicines are increasingly popular among people with multiple sclerosis (MS) in the northwestern United States, a survey…
MS Imaging Startup Among 8 Minority-owned Firms Earning Investment
JuneBrain, a startup company that is developing a wearable head imaging device that enables multiple sclerosis (MS) patients to…
Tecfidera Safe and Effective Over Years of Use, RRMS Study Finds
Tecfidera (dimethyl fumarate) is safe and effective as a long-term treatment for relapsing-remitting multiple sclerosis (RRMS), a study…
NICE Does Not Favor Adding Mayzent to NHS England for Active SPMS
The National Institute for Health and Care Excellence (NICE) is recommending against Mayzent (siponimod) as a treatment for active…
University Study of Falls During COVID-19 Enrolling Patients for Online Survey
A study aiming to better understand falls and fall-related injuries in people with multiple sclerosis (MS) and other neurological disorders…
NIH Backs Project Examining Failure of Immune Tolerance Leading to Autoimmune Disease
A new research project will seek to understand the development of immune cells that drive autoimmune diseases such as multiple…
Icompanion App Enables Patients to Track Symptoms, Understand MRI Scans
Icometrix launched a new digital platform, icompanion, to help people with multiple sclerosis (MS) track their disease and…
FDA Extends Review of Ofatumumab for Relapsing MS to September
The U.S. Food and Drug Administration (FDA) is extending its review of Novartis‘Â ofatumumab, a possible self-administered injection…
Zeposia, Daily Oral Treatment for Relapsing MS, Now Available in US
Zeposia (ozanimod), a newly approved oral capsule treatment for relapsing forms of multiple sclerosis (MS), is now commercially…
Pain and Disturbed Sleep May Be Earliest Symptoms of MS, Study Suggests
Symptoms including sleep disorders and pain may precede by as many as five years the onset of the more…
Multiarm Trial Fails at SPMS Treatment, But Shows New Way Forward for Studies
A clinical trial testing Midamor (amiloride), Prozac (fluoxetine),…
Zeposia Receives European Commission Approval for Adults with Active RRMS
The European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS)…
Higher Blood NfL Levels Predict Worse Disability Over Time in MS, Study Suggests
Higher blood levels of the neurofilament light chain (NfL) protein at diagnosis are predictive of worse disability over time in…
Evobrutinib Lowers MS Relapse Rates Over 2 Years of Use, Trial Data Show
Note: This story was updated May 27, 2020, to note a change in the protocol of the EVOLUTION trials,…